Table 2.
Patient characteristics
| |
Patients (N = 100) |
|
|---|---|---|
| Characteristics | No. | |
| Age, years |
|
|
| Median |
|
69 |
| Range |
|
51-92 |
| ECOG performance status |
|
|
| 0 |
91 |
|
| 1 |
9 |
|
| HLA typing |
|
|
| A24 |
66 |
|
| A2 |
21 |
|
| A3 supertype |
11 |
|
| A26 |
2 |
|
| Baseline PSA, ng/ml |
|
|
| Median |
|
29.8 |
| Range |
|
0.2-2481 |
| PSADT, months |
|
|
| Median |
|
2 |
| Range |
|
0.3-36+ |
| Lymphocyte, 1300/μL |
|
|
| Low |
41 |
|
| High |
59 |
|
| CRP, 3 μg/mL |
|
|
| Low |
53 |
|
| High |
47 |
|
| SAA, 8 μg/mL |
|
|
| Low |
27 |
|
| High |
76 |
|
| IL6, 2.4 pg/mL |
|
|
| Low |
84 |
|
| High |
16 |
|
| Gleason score |
|
|
| ≤7 |
34 |
|
| ≥8 |
57 |
|
| Unknown |
9 |
|
| Site of metastasis |
|
|
| no |
14 |
|
| Bone only |
33 |
|
| Bone and nodal/organ |
40 |
|
| Nodal/organ |
13 |
|
| Prior chemotherapy |
|
|
| (-) |
60 |
|
| (+) | 40 | |
Abbreviations: PPV, personalized peptide vaccination; ECOG, Eastern Cooperative Oncology Group; HLA, human leucocyte antigen; PSA, prostate-specific antigen; PSADT, PSA doubling time; CRP, C-reactive protein; SAA, serum amyloid A; IL6, interleukin 6.